EA201791166A1 - Препараты с контролируемым высвобождением - Google Patents
Препараты с контролируемым высвобождениемInfo
- Publication number
- EA201791166A1 EA201791166A1 EA201791166A EA201791166A EA201791166A1 EA 201791166 A1 EA201791166 A1 EA 201791166A1 EA 201791166 A EA201791166 A EA 201791166A EA 201791166 A EA201791166 A EA 201791166A EA 201791166 A1 EA201791166 A1 EA 201791166A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- precursor
- present
- preparation
- preparations
- liquid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Настоящее изобретение относится к составам для получения лекарственной формы, содержащим имеющие низкую вязкость нежидкокристаллические смеси: a) по меньшей мере одного сложного эфира сахара или производного сахара; b) по меньшей мере одного фосфолипида; c) по меньшей мере одного биосовместимого кислородсодержащего имеющего низкую вязкость органического растворителя; причем указанный препарат-предшественник образует или способен образовывать по меньшей мере одну структуру жидкокристаллической фазы при контакте с водной жидкостью, при условии, что указанный препарат-предшественник не содержит дополнительно отвердитель жидких кристаллов. Указанные препараты-предшественники подходят для получения вводимых парентерально, не парентерально и топически депо-композиций для пролонгированного высвобождения активных агентов. Настоящее изобретение дополнительно относится к способу доставки активного агента, включающему введение препарата-предшественника согласно настоящему изобретению, депо-композиции, образующейся в результате контакта препаратов-предшественников согласно настоящему изобретению с водной жидкостью, способу лечения, включающему введение препарата-предшественника согласно настоящему изобретению, и применению препарата-предшественника согласно настоящему изобретению.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201423134 | 2014-12-23 | ||
PCT/EP2015/081191 WO2016102683A1 (en) | 2014-12-23 | 2015-12-23 | Controlled-release formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201791166A1 true EA201791166A1 (ru) | 2017-12-29 |
EA033590B1 EA033590B1 (ru) | 2019-11-07 |
Family
ID=55071020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201791166A EA033590B1 (ru) | 2014-12-23 | 2015-12-23 | Препараты с контролируемым высвобождением |
Country Status (13)
Country | Link |
---|---|
US (2) | US20180000943A1 (ru) |
EP (1) | EP3236937B1 (ru) |
JP (1) | JP6822962B2 (ru) |
KR (1) | KR20170099978A (ru) |
CN (1) | CN107257681A (ru) |
AU (1) | AU2015370922B2 (ru) |
BR (1) | BR112017013471A2 (ru) |
CA (1) | CA2971642A1 (ru) |
EA (1) | EA033590B1 (ru) |
IL (1) | IL253042B (ru) |
SG (1) | SG11201705155SA (ru) |
WO (1) | WO2016102683A1 (ru) |
ZA (1) | ZA201704263B (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3215223T3 (da) | 2014-11-07 | 2020-08-03 | Indivior Uk Ltd | Buprenorphindoseringsskemaer |
IL295457A (en) | 2016-09-27 | 2022-10-01 | Camurus Ab | Mixtures and formulations containing alkyl ammonium salt edta |
US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
CN108771657B (zh) * | 2017-06-22 | 2020-11-06 | 四川大学 | 一种小分子药物原位相变凝胶缓释***及其制备方法 |
WO2019099735A1 (en) * | 2017-11-15 | 2019-05-23 | Rhythm Pharmaceuticals, Inc. | Sustained release peptide formulations |
CN112955181A (zh) * | 2019-03-26 | 2021-06-11 | 新型医药公司 | 一种长效脂肪酸缀合的GnRH衍生物及含其的药物组合物 |
CN111643483B (zh) * | 2020-07-06 | 2022-03-29 | 济南大学 | 一种用于制备加兰他敏缓释微球的方法 |
EP4378452A1 (en) | 2021-07-27 | 2024-06-05 | Farnex Incorporated | Non-lamellar liquid crystal-forming composition and use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5127449B2 (ja) * | 2004-06-04 | 2013-01-23 | カムルス エービー | 流体デポ製剤 |
GB0412530D0 (en) * | 2004-06-04 | 2004-07-07 | Camurus Ab | Formulation |
WO2013030838A2 (en) * | 2011-08-29 | 2013-03-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Dendrimer-lyotropic liquid crystal (llc) systems |
KR101494594B1 (ko) * | 2011-08-30 | 2015-02-23 | 주식회사 종근당 | 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
JP6081480B2 (ja) * | 2011-12-05 | 2017-02-15 | カムルス エービー | 頑強な徐放性製剤 |
GB201205642D0 (en) * | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
KR101586791B1 (ko) * | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | GnRH 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
-
2015
- 2015-12-23 EA EA201791166A patent/EA033590B1/ru not_active IP Right Cessation
- 2015-12-23 EP EP15820533.6A patent/EP3236937B1/en active Active
- 2015-12-23 CA CA2971642A patent/CA2971642A1/en not_active Abandoned
- 2015-12-23 KR KR1020177020439A patent/KR20170099978A/ko not_active Application Discontinuation
- 2015-12-23 CN CN201580070606.5A patent/CN107257681A/zh active Pending
- 2015-12-23 BR BR112017013471A patent/BR112017013471A2/pt not_active Application Discontinuation
- 2015-12-23 JP JP2017533914A patent/JP6822962B2/ja active Active
- 2015-12-23 WO PCT/EP2015/081191 patent/WO2016102683A1/en active Application Filing
- 2015-12-23 US US15/538,279 patent/US20180000943A1/en not_active Abandoned
- 2015-12-23 AU AU2015370922A patent/AU2015370922B2/en active Active
- 2015-12-23 SG SG11201705155SA patent/SG11201705155SA/en unknown
-
2017
- 2017-06-20 IL IL253042A patent/IL253042B/en active IP Right Grant
- 2017-06-22 ZA ZA2017/04263A patent/ZA201704263B/en unknown
-
2020
- 2020-07-27 US US16/939,778 patent/US20200353086A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20200353086A1 (en) | 2020-11-12 |
JP2018502091A (ja) | 2018-01-25 |
IL253042B (en) | 2020-08-31 |
ZA201704263B (en) | 2019-09-25 |
BR112017013471A2 (pt) | 2018-02-27 |
US20180000943A1 (en) | 2018-01-04 |
EA033590B1 (ru) | 2019-11-07 |
WO2016102683A1 (en) | 2016-06-30 |
SG11201705155SA (en) | 2017-07-28 |
KR20170099978A (ko) | 2017-09-01 |
EP3236937B1 (en) | 2022-05-04 |
AU2015370922A1 (en) | 2017-07-06 |
CA2971642A1 (en) | 2016-06-30 |
EP3236937A1 (en) | 2017-11-01 |
AU2015370922B2 (en) | 2018-10-04 |
JP6822962B2 (ja) | 2021-01-27 |
IL253042A0 (en) | 2017-08-31 |
NZ732827A (en) | 2023-11-24 |
CN107257681A (zh) | 2017-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201791166A1 (ru) | Препараты с контролируемым высвобождением | |
ZA202102906B (en) | Liquid protein formulations containing viscosity-lowering agents | |
MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
EA201491005A1 (ru) | Устойчивые составы с контролируемым высвобождением | |
MY177820A (en) | Controlled release peptide formulations | |
EA201792421A1 (ru) | Амидозамещенные производные циклогексана | |
AR105493A1 (es) | Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h | |
BR112012015433A2 (pt) | composição farmacêutica substancialmente anidra para aplicação cutânea | |
EA201890906A1 (ru) | ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
CL2019001746A1 (es) | Amidas aromáticas de ácido carboxílico | |
EA201591649A1 (ru) | Составы с органическими соединениями | |
BR112015022290A2 (pt) | derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120 | |
BR112016001948A2 (pt) | antagonistas de v1a para tratar distúrbios do sono de desvio de fase | |
EA201690077A1 (ru) | Терапевтически активные производные эстратриен-тиазола | |
CL2016003063A1 (es) | Composición basada en una solución estabilizada de ingredientes activos | |
MX2019002999A (es) | Formulaciones de analogo de prostaciclina. | |
EA201690626A1 (ru) | Новый состав гонадотропинов | |
EA201990046A1 (ru) | Производные бициклического пиридина, пиразина и пиримидина в качестве ингибиторов pi3k бета | |
CO2018000526A2 (es) | Concentrado que contiene alprostadil | |
PE20171305A1 (es) | Formulaciones inyectables de paracetamol | |
CO2018000525A2 (es) | Concentrado que contiene alprostadil | |
TH167877B (th) | สูตรผสมใหม่สำหรับโกนาโดโทรพิน | |
TH167877A (th) | สูตรผสมใหม่สำหรับโกนาโดโทรพิน | |
EA201992296A1 (ru) | Производные хиноксалина и пиридопиразина в качестве ингибиторов pi3k-бета | |
CO2016004668A2 (es) | Composición basada en una solución estabilizada de ingredientes activos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |